首页|信迪利单抗联合紫杉醇、铂类药物化疗治疗晚期宫颈癌效果及对血清肿瘤标志物、免疫功能影响

信迪利单抗联合紫杉醇、铂类药物化疗治疗晚期宫颈癌效果及对血清肿瘤标志物、免疫功能影响

扫码查看
目的 探究信迪利单抗联合紫杉醇、铂类药物化疗治疗晚期宫颈癌效果及对血清肿瘤标志物、免疫功能等影响.方法 选取2020 年6 月—2023 年6 月收治的晚期宫颈癌80 例,根据治疗方法不同将其分为观察组和对照组2 组各40 例.观察组给予信迪利单抗联合紫杉醇、铂类药物化疗,对照组给予紫杉醇和铂类药物化疗.比较 2组治疗4 个疗程临床效果,治疗前和治疗2、4 个疗程肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、鳞状细胞癌抗原(SCC-Ag)、肿瘤相关物质群(TSGF)]、血管内皮生长因子(VEGF)、转化生长因子-β1(TGF-β1)、人白细胞抗原-G(HLA-G)、免疫功能(CD4 +、CD3 +、CD4 +/CD8 +),以及治疗过程中不良反应.结果 观察组疾病控制率为82.50%(33/40)高于对照组 62.50%(25/40)(P<0.05).治疗 2 和 4 个疗程,2 组 CEA、CA125、SCC-Ag、TSGF和VEGF、TGF-β1、HLA-G均低于治疗前,且观察组低于对照组;2 组CD4 +、CD3 +、CD4 +/CD8 +均低于治疗前,但观察组高于对照组(P<0.01,P<0.05).治疗过程中,2 组各项不良反应总发生率比较差异无统计学意义(P>0.05).结论 信迪利单抗联合紫杉醇、铂类药物化疗治疗晚期宫颈癌患者效果可靠,可下调血清肿瘤标志物和VEGF、TGF-β1、HLA-G水平,稳定机体免疫,且不增加不良反应.
Effects of Sintillizumab Combined with Paclitaxel and Platinum-based Chemotherapy Drugs in Patients with Advanced Cervical Cancer and Their Effect on Serum Tumor Markers and Immune Function
Objective To investigate the effects of Sindilizumab combined with Paclitaxel and Platinum-based chemo-therapy drugs on advanced cervical cancer,and their effect on serum tumor markers and immune function.Methods A total of 80 patients with advanced cervical cancer admitted to our hospital from June 2020 to June 2023 were selected and divided into the observation group(n =40)and the control group(n =40)according to different treatment methods.The observation group was given Sindilizumab combined with Paclitaxel and Platinum-based chemotherapy drugs,and the control group was given Paclitaxel and Platinum-based chemotherapy drugs.The clinical effect after 4 courses of treatment,tumor markers[car-cinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),squamous cell carcinoma antigen(SCC-Ag),tumor sup-plied group of factors(TSGF)],vascular endothelial growth factor(VEGF),transforming growth factor β1(TGF-β1),hu-man leukocyte antigen G(HLA-G),and immune functions[CD4 +,CD3 +,CD4 +/CD8 +]before and after 2 and4 cour-ses of treatment,as well as adverse reactions during treatment,were compared between the two groups.Results The disease control rate(DCR)in the observation group was 82.50%(33/40),which was higher than that in the control group[62.50%(25/40)](P<0.05).CEA,CA125,SCC-Ag,TSGF,VEGF,TGF-β1 and HLA-G in the two groups were lower than those before treatment,which were lower in observation group than in control group after 2 courses of treatment and 4 courses of treatment;CD4 +,CD3 +,and CD4 +/CD8 + in the two groups were lower than those before treatment,which were higher in observation group than in control group(P<0.01,P<0.05).There was no significant difference in total inci-dence of adverse reactions between the two groups(P>0.05).Conclusion Sindelizumab combined with Paclitaxel and Platinum-based chemotherapy drugs has a reliable effect in the treatment of advanced cervical cancer patients,which can down-regulate serum tumor markers and the levels of VEGF,TGF-β1 and HLA-G,stabilize immunity,and do not increase adverse reactions.

Uterine cervical neoplasmsAdvancedSindilimabPaclitaxelPlatinumCarcinoembryonic antigenVascular endothelial growth factorCD4 +

查镜娟、郑晓霆、吴生保

展开 >

239300 安徽 天长,天长市中医院肿瘤科

宫颈肿瘤 晚期 信迪利单抗 紫杉醇 铂类药物 癌胚抗原 血管内皮生长因子 CD4 +

安徽省中央引导地方科技发展专项项目

YDZX20183400004622

2024

转化医学杂志
海军总医院

转化医学杂志

CSTPCD
影响因子:0.671
ISSN:2095-3097
年,卷(期):2024.13(2)
  • 6